Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dabrafenib plus Trametinib in BRAF-mutant Melanoma Brain Metastases
NCT02039947Phase 2Completed
- Sponsor
- Novartis
- Start
- Feb 2014
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of dabrafenib + trametinib, trametinib in melanoma, brain metastases, sponsored by Novartis. Started Feb 2014; status: completed.
02
Drugs
dabrafenib + trametinibtrametinib
03
Conditions
melanomabrain metastases
Beyond the preview
Go deeper on NCT02039947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02039947.